Create Medicines secured a $122 million Series B to advance its in vivo immune programming platform for autoimmune disease and oncology. The funding supports pipeline progression across repeat-dose programs, including CRT-402, a CD19-targeted in vivo CAR T approach showing deep B-cell depletion in non-human primates, and an oncology program targeting MT-303 for hepatocellular carcinoma.